SCHEMBL6489553

SCHEMBL6489553

Clc1cccc(Cl)c1CSc1n[nH]c(-c2cnccn2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.55
LMNA P02545 1/20 0.55
PIEZO1 Q92508 5/20 0.53
GRK6 P43250 1/20 0.53
NPC1 O15118 3/20 0.44
ALDH1A1 P00352 2/20 0.44
ROCK2 O75116 2/20 0.44
MAP4K4 O95819 1/20 0.44
PRKX P51817 1/20 0.44
AURKB Q96GD4 1/20 0.44
CLK4 Q9HAZ1 1/20 0.44
SGK2 Q9HBY8 1/20 0.44
MAP4K5 Q9Y4K4 1/20 0.44
POLB P06746 2/20 0.43
GRK2 P25098 1/20 0.43
PLA2G1B P04054 1/20 0.43
MAPT P10636 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ATG4B Q9Y4P1 1/20 0.43
GPR55 Q9Y2T6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14027202 0.72 SMN1; SMN2 (1.00) SMN1; SMN2LMNAALDH1A1POLBPLA2G1B
SCHEMBL6490578 0.69 PIEZO1 (1.00) SMN1; SMN2LMNAPIEZO1NPC1ALDH1A1
SCHEMBL17280119 0.65 SMN1; SMN2 (0.59) SMN1; SMN2GRK6NPC1ALDH1A1MAPT
SCHEMBL17279720 0.65 SMN1; SMN2 (0.71) SMN1; SMN2LMNANPC1L3MBTL1RAB9A
SCHEMBL11320053 0.64 SMN1; SMN2 (0.53) SMN1; SMN2GRK6NPC1L3MBTL1RAB9A
SCHEMBL29712839 0.64 METAP2 (0.42) SMN1; SMN2PIEZO1GRK6NPC1ALDH1A1
SCHEMBL28634816 0.64 METAP2 (0.42) SMN1; SMN2PIEZO1GRK6NPC1ALDH1A1
SCHEMBL5484113 0.64 SMN1; SMN2 (0.82) SMN1; SMN2LMNAALDH1A1KMT2AMEN1
SCHEMBL7486893 0.64 PIEZO1 (0.47) SMN1; SMN2PIEZO1NPC1ALDH1A1RAB9A
SCHEMBL1927150 0.63 KDM4E (0.47) SMN1; SMN2GRK6NPC1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073726-A1 Heterocyclic inhibitors of glycine transporter 2 TELIK, INC. 2003-04-17 US claimed
US-6894054-B2 Heterocyclic inhibitors of glycine transporter 2 TELIK, INC. (US) 2005-05-17 US disclosed
US-20030073726-A1 Heterocyclic inhibitors of glycine transporter 2 TELIK, INC. 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073726-A1 Heterocyclic inhibitors of glycine transporter 2 SLC1A2, SLC1A1, SLC1A3 SMN1; SMN2 210/4885LMNA 3529/4885PIEZO1 2298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.